Figure 4 illustrates the pathophysiological steps leading to MASLD/MASH and HCC progression that are associated to STAT6 activity or that can be targeted by STAT6 modulators and Table 2 described experimental details of studies investigating the role of STAT6 in this context. Here, STAT6 is linked to hepatocellular carcinoma.